Evidence map›Paper›PMID 34373552›Full record

ArticleScientific reports2021

Transportation protocols for accurate assessment of microbial burden classification using molecular methods.

Amelia Kung, Jade Chen, Michael Tomasek, Dakai Liu, William Rodgers, Vincent Gau

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Amelia Kung *GeneFluidics, Los Angeles, CA, USA.
Jade Chen *GeneFluidics, Los Angeles, CA, USA.
Michael TomasekGeneFluidics, Los Angeles, CA, USA.
Dakai LiuDepartment of Pathology and Clinical Laboratories, New York-Presbyterian Queens, Flushing, NY, USA.
William RodgersDepartment of Pathology and Clinical Laboratories, New York-Presbyterian Queens, Flushing, NY, USA.
Vincent GauGeneFluidics, Los Angeles, CA, USA. vgau@genefluidics.com.
GeneFluidics (United States) · USNew York Hospital Queens · US

Funding

Safe and Effective Whole Blood ID/AST Device for Use in Neonatal ICU SettingsR44HD084033 · NICHD · GENEFLUIDICS, INC. · PI GAU, VINCENT JEN-JR · 2015 to 2021
$4.6M
A fully integrated CentriFluidic system for direct bloodstream infection PID/ASTR01AI117059 · NIAID · GENEFLUIDICS, INC. · PI GAU, VINCENT JEN-JR · 2015 to 2019
$3.6M
Near patient molecular diagnostics test for infectionsSB1AI088756 · NIAID · GENEFLUIDICS, INC. · PI GAU, VINCENT JEN-JR · 2016 to 2018
$3.0M
NIAID NIH HHS R01 AI117059NIAID NIH HHS SB1 AI088756NICHD NIH HHS R44 HD084033
6 · The paper itself

Abstract

Point-of-care testing is cost-effective, rapid, and could assist in avoiding hospital visits during a pandemic. However, they present some significant risks that current technologies cannot fully address. Skin flora contamination and insufficient specimen volume are two major limitations preventing self-collection microbiological testing outside of hospital settings. We are developing a hybrid testing procedure to bridge the laboratory test with patient-side specimen collection and transportation for molecular microbial classification of causative bacterial infection and early identification of microbial susceptibility profiles directly from whole blood or urine specimens collected patient-side by health care workers such as phlebotomists in nursing homes or family clinics. This feasibility study presents our initial development efforts, in which we tested various transportation conditions (tubes, temperature, duration) for direct-from-specimen viable pathogen detection to determine the ideal conditions that allowed for differentiation between contaminant and causative bacteria in urine specimens and optimal growth for low-concentration blood specimens after transportation. For direct-from-urine assays, the viable pathogen at the clinical cutoff of 10

Indexed as

BacteriaBacterial InfectionsCost-Benefit AnalysisHumansNursing HomesPoint-of-Care TestingSkinSpecimen HandlingTransportation

Identifiers

PMID34373552
PMCPMC8352943
OpenAlexW3191246799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.